{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-25-000729","form_type":"8-K","ticker":"BGMS","cik":"0001130166","company_name":"Bio Green Med Solution, Inc.","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.999765+00:00","generated_at":"2026-05-27T02:22:56.344053+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cyclacel places UK subsidiary into CVL; to buy plogosertib, sell fadraciclib","bullets":["UK subsidiary Cyclacel Ltd entered creditors voluntary liquidation; joint liquidators appointed.","Company plans to purchase plogosertib from liquidators for new oral formulation development.","Fadraciclib program will be marketed for sale by liquidators and removed from company assets.","Deconsolidation expected to increase stockholders' equity by approximately $5.6M in Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-25-000729","json":"https://secwatch.observer/filing/0001829126-25-000729.json","markdown":"https://secwatch.observer/filing/0001829126-25-000729.md","text":"https://secwatch.observer/filing/0001829126-25-000729.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130166/000182912625000729/0001829126-25-000729-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130166/000182912625000729/cyclacelpharma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:22:56.344053+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}